HLB Life Science Co. Ltd (067630) — Cash Flow-to-Debt Ratio
HLB Life Science Co. Ltd (067630) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of ₩-4.30 Billion could theoretically repay 0% of its total liabilities (₩173.00 Billion) in one year. Explore HLB Life Science Co. Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HLB Life Science Co. Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for HLB Life Science Co. Ltd across 13 annual periods. Also explore how large is HLB Life Science Co. Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for HLB Life Science Co. Ltd (2012–2024)
Year-by-year debt coverage analysis for HLB Life Science Co. Ltd. For market capitalisation and broader financial context, see HLB Life Science Co. Ltd (067630) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | ₩-32.01 Billion | ₩140.19 Billion | ▼ -338.3% |
| 2023 | -0.05x | ₩-10.02 Billion | ₩192.29 Billion | ▲ +69.0% |
| 2022 | -0.17x | ₩-29.74 Billion | ₩177.07 Billion | ▲ +70.6% |
| 2021 | -0.57x | ₩-14.08 Billion | ₩24.61 Billion | ▼ -1239.3% |
| 2020 | 0.05x | ₩2.01 Billion | ₩40.02 Billion | ▲ +128.8% |
| 2019 | -0.17x | ₩-12.39 Billion | ₩71.11 Billion | ▼ -163.0% |
| 2018 | -0.07x | ₩-11.07 Billion | ₩167.17 Billion | ▼ -913.0% |
| 2017 | -0.01x | ₩-302.04 Million | ₩46.19 Billion | ▲ +84.2% |
| 2016 | -0.04x | ₩-2.27 Billion | ₩54.99 Billion | ▲ +84.0% |
| 2015 | -0.26x | ₩-4.34 Billion | ₩16.80 Billion | ▼ -149.4% |
| 2014 | 0.52x | ₩10.43 Billion | ₩19.95 Billion | ▲ +559.4% |
| 2013 | 0.08x | ₩2.95 Billion | ₩37.19 Billion | ▼ -78.0% |
| 2012 | 0.36x | ₩13.97 Billion | ₩38.83 Billion | — |